PriceTargets.com logo

Almirall - LBTSF Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$9.51 As of 04/30/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for LBTSF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Almirall Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LBTSF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LBTSF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Almirall in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $9.51.

This chart shows the closing price for LBTSF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Almirall. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/6/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/7/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/5/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/14/2022Royal Bank of CanadaLower Target€13.50 ➝ €13.00
11/11/2022Morgan StanleyLower TargetEqual Weight ➝ Equal Weight€12.50 ➝ €11.50
10/19/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight
9/28/2022Royal Bank of CanadaInitiated CoverageOutperform
9/15/2022Credit Suisse GroupLower TargetNeutral ➝ Neutral€12.00 ➝ €10.00
7/26/2022Morgan StanleyLower Target€16.25 ➝ €16.00
2/23/2022Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
11/17/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
9/8/2021Morgan StanleyInitiated CoverageOverweight
3/29/2021The Goldman Sachs GroupUpgradeNeutral ➝ Buy
10/6/2020Credit Suisse GroupReiterated RatingNeutral
7/21/2020Credit Suisse GroupDowngradeOutperform ➝ Neutral
7/15/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral
5/8/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy
5/2/2019Jefferies Financial GroupUpgradeHold ➝ Buy
(Data available from 5/1/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2023
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/2/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/1/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/1/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Almirall logo
Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Read More

Today's Range

Now: $9.51
Low: $9.51
High: $9.51

50 Day Range

MA: $9.51
Low: $9.51
High: $9.51

52 Week Range

Now: $9.51
Low: $8.85
High: $10.18

Volume

1 shs

Average Volume

200 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Almirall?

The following Wall Street research analysts have issued stock ratings on Almirall in the last year:
View the latest analyst ratings for LBTSF.

What is the current price target for Almirall?

0 Wall Street analysts have set twelve-month price targets for Almirall in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Almirall in the next year.
View the latest price targets for LBTSF.

What is the current consensus analyst rating for Almirall?

Almirall currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for LBTSF.

What other companies compete with Almirall?

Other companies that are similar to Almirall include 1933 Industries, 4Cable TV International, 4Front Ventures, AB Science and Abacus Health Products. Learn More about companies similar to Almirall.

How do I contact Almirall's investor relations team?

Almirall's physical mailing address is Ronda General Mitre, 151, Barcelona, Catalonia 08022. The company's listed phone number is 34 93 291 30 00. The official website for Almirall is www.almirall.com. Learn More about contacing Almirall investor relations.